Adrenal Insufficiency Clinical Trial
— MAdEyOfficial title:
Management of Adrenal Emergency in Germany - a Prospective Multicenter
Verified date | February 2018 |
Source | Wuerzburg University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The management of adrenal crisis is often problematic and the time to adequate treatment is frequently delayed.The aim of the study is to evaluate the management of adrenal emergencies requiring parenteral glucocorticoid treatment by a prospective multicenter study in patients with chronic adrenal insufficiency.
Status | Completed |
Enrollment | 150 |
Est. completion date | November 2017 |
Est. primary completion date | November 2017 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age =18 years - Documented chronic adrenal insufficiency - Established corticosteroid replacement therapy - Written informed consent Exclusion Criteria: - Age <18 years |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Wuerzburg University Hospital | Endocrinology in Charlottenburg, Berlin, Germany, University Hospital, Frankfurt, Germany |
Allolio B. Extensive expertise in endocrinology. Adrenal crisis. Eur J Endocrinol. 2015 Mar;172(3):R115-24. doi: 10.1530/EJE-14-0824. Epub 2014 Oct 6. Review. — View Citation
Hahner S, Hemmelmann N, Quinkler M, Beuschlein F, Spinnler C, Allolio B. Timelines in the management of adrenal crisis - targets, limits and reality. Clin Endocrinol (Oxf). 2015 Apr;82(4):497-502. doi: 10.1111/cen.12609. Epub 2014 Nov 6. — View Citation
Hahner S, Spinnler C, Fassnacht M, Burger-Stritt S, Lang K, Milovanovic D, Beuschlein F, Willenberg HS, Quinkler M, Allolio B. High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. J Clin Endocrinol Metab. 2015 Feb;100(2):407-16. doi: 10.1210/jc.2014-3191. Epub 2014 Nov 24. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Median time from contacting a medical professional to arrival of professional medical help | Evaluation of the median time (in minutes) from contacting a medical professional (by the patient) to arrival of professional medical help during an (adrenal) emergency. The time is documented in a questionnaire by the patients themselves (directly after the adrenal emergency). The data of all patients will be stated as median and range. |
6-36 months | |
Primary | Median time from showing the emergency card (by a patient) to glucocorticoid-injection by a medical professional | Evaluation of the median time (in minutes) from showing the emergency card (by a patient) to glucocorticoid-injection by a medical professional. The time is documented in a questionnaire by the patients themselves (directly after the adrenal emergency). The data of all patients will be stated as median and range. |
6-36 months | |
Primary | Median time from the beginning of symptoms to glucocorticoid-injection | Evaluation of the median time (in minutes) from the beginning of symptoms to glucocorticoid-injection during an (adrenal) emergency. The time is documented in a questionnaire by the patients themselves (directly after the adrenal emergency). The data of all patients will be stated as median and range. |
6-36 months | |
Primary | Duration of hospitalisation (number of days at a hospital) | Evaluation of the duration of hospitalisation (number of days at a hospital) due to an adrenal emergency. The number of days is documented by the patients themselves (directly after the adrenal emergency). The data of all patients will be stated as median and range. |
6-36 months | |
Primary | Number of patients that received an intramuscular glucocorticoid-injection | Evaluation of the number of patients that received an intramuscular glucocorticoid-injection (compared to subcutaneous administration) during an adrenal emergency. Documentation by the patients themselves directly after the adrenal emergency. | 6-36 months | |
Secondary | Cause of the adrenal emergency | Evaluation of the causes of the adrenal emergencies. The causes are documented in a questionnaire by the patients themselves. The number of different causes that are stated by all patients will be evaluated. | 6-36 months | |
Secondary | Median time from the beginning of symptoms to oral dose adjustment (glucocorticoids) during an adrenal emergency | Evaluation of the median time (in minutes) from the beginning of symptoms to oral dose adjustment (glucocorticoids). The time is documented in a questionnaire by the patients themselves (directly after the adrenal emergency). The data of all patients will be stated as median and range. |
6-36 months | |
Secondary | Median time from the beginning of symptoms to contacting a medical professional | Evaluation of the median time (in minutes) from the beginning of symptoms to contacting a medical professional during an adrenal emergency. The time is documented in a questionnaire by the patients themselves (directly after the adrenal emergency). The data of all patients will be stated as median and range. |
6-36 months | |
Secondary | Symptoms of the adrenal emergency | Evaluation of the symptoms during the adrenal emergencies. The symptoms are documented in a questionnaire by the patients themselves. The number of different symptoms that are stated by all patients will be evaluated. | 6-36 months | |
Secondary | Median amount of additionally oral ingested glucocorticoids during the adrenal emergency | Evaluation of the median amount of additionally oral ingested glucocorticoids (in mg) during the adrenal emergency. The amount of glucocorticoids is documented in a questionnaire by the patients themselves (directly after the adrenal emergency). The data of all patients will be stated as median and range. |
6-36 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT03282487 -
Optimising Steroid Replacement in Patients With Adrenal Insufficiency
|
Phase 4 | |
Not yet recruiting |
NCT06435481 -
Tolerability and Acceptance of Two Oral Hydrocortisone Compounding Formulation for Pediatrics
|
Phase 4 | |
Not yet recruiting |
NCT05716607 -
Treatment Study in Patients Treated With Both Insulin & Hydrocortisone
|
N/A | |
Recruiting |
NCT03399383 -
Adherence in Chronic Adrenal Insufficiency
|
N/A | |
Completed |
NCT01428336 -
Value of 25 mcg Cortrosyn Stimulation Test
|
N/A | |
Completed |
NCT00851942 -
Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test
|
Phase 4 | |
Withdrawn |
NCT00368381 -
Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis
|
Phase 4 | |
Active, not recruiting |
NCT04519580 -
Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
|
||
Recruiting |
NCT06008184 -
Real-time Monitoring of Cortisol - Comparison of Cortisol Levels in Four Biological Fluids
|
||
Completed |
NCT03013166 -
THIN Database Study: Resource Use and Outcomes in Patients With Adrenal Insufficiency Prescribed Hydrocortisone: Immediate, or Modified Release, or Prednisolone
|
||
Enrolling by invitation |
NCT02282150 -
Modified-release Compared to Conventional Hydrocortisone on Diurnal Fatigue in Secondary Hypoadrenalism
|
Phase 4 | |
Completed |
NCT02934399 -
Dynamic Hormone Diagnostics in Endocrine Disease
|
||
Completed |
NCT03000231 -
Circadian Function and Cardio-metabolic Risk in Adrenal Insufficiency
|
||
Completed |
NCT01960530 -
An Investigational Study of Hydrocortisone
|
Phase 1 | |
Completed |
NCT00552487 -
Isolated ACTH Deficiency in Patients With Hashimoto Thyroiditis
|
N/A | |
Completed |
NCT00575341 -
Dehydroepiandrosterone Substitution in Adolescent and Young Women With Central Adrenal Insufficiency
|
Phase 3 | |
Completed |
NCT00471900 -
Six Months DHEA Treatment in Female Adrenal Failure
|
N/A | |
Completed |
NCT03294876 -
Rheumatoid Arthritis Adrenal Recovery Study
|
||
Completed |
NCT03709381 -
Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study
|
Early Phase 1 | |
Recruiting |
NCT05639127 -
The Treatment of Adrenal Crisis With Inhaled Prednisolone
|
Early Phase 1 |